INTRODUCTION
Photodynamic therapy (PDT) using hematoporphyrin derivative as an effective modality in the management ofcancer is currently receiving considerable attention (1) (2) (3) . The photosensitizer preparation most commonly used is a complex mixture of porphyfins termed hematoporphyrin derivative (HpD) or Photofrin, a partially purified preparation of HpD, which received government approval on October 1994 in Japan. In spite ofexcellent results in clinical studies, especially in early-stage lung cancer, wider clinical applications of PDT using HpD are hampered by the skin photosensitivity it induces (4, 5) . Photofrin has routinely been given intravenously at a dosage of 2.0 mg/kg body weight since the report of Dougherty et al. (6) ; however, patients receiving Photofrin must avoid sunlight for a minimum of 30 days to avoid sunburn (4) .
On the other hand, regional infusion of anticancer agents into the malignant lesion via a transarterial route could minimize fast deactivation while increasing the anticancer effect (7) . Bronchial artery infusion (BAI) is known to achieve high concentrations of anticancer drug (8) . To reduce skin photosensitivity and to increase local photodynamic effects, a clinical study of low-dose Photofrin given by BAI was performed.
MATERIALS AND METHODS

Patient Selection
The patients and their histories are outlined in Table 1 
Hamamatsu, Japan) (9). The excimer laser uses a gas mixture containing 0.9% Xe, 0.1% HC1, and 99% helium at 2 atm pressure. The optimal performance of this laser is obtained at 30 rnJ/pulse with one-halfpeak power x 10.9 nsec at 308 nm. The XeC1 excimer laser (308 nm) can be coupled to a pump system, which contains 2 M Rhodamine B dye in ethanol to convert the beam to 630 nm. The beams from the excimer-dye lasers were focused onto 400 I.tm fused silica fibers (Moritex Ltd, Nagoya, Japan), the tips of which were fitted with microlens to improve the homogeneity of light distribution throughout the treatment field. The final circular area of illumination was 1 cm2. Illumination times ranged from 10-40 mins, giving energy densities of 100 to 200 J/cm2.
The tumor response to PDT was evaluated endoscopically, roentgenographically, cytologically, and histologically 1 month after treatment. Tumor response was classified into three categories: complete remission (CR), partial remission (PR), and no change (NC). CR was defined as the complete absence of tumor endoscopically as well as both cytologically and histologically. PR was defined as a 50% or more reduction in tumor volume estimated macroscopically or histologically, and NC was defined as a reduction in tumor volume of less than 50%.
Skin photosensitivity was tested within 72 hr after Photofrin administration (10) . Testing was done on the lower back. Test rectangles 1.5 by 2.5 cm were exposed to visible light (400 to 750 nm) to cover the entire visible absorption spectrum of Photofrin. The light source for testing was a 500 W projector lamp with a filter to remove infrared light. The test light power density was 30 J/cm2. Skin reaction was evaluated 24 hr after light exposure. This was graded as 0, 1+, 2+, or 3+. Grade 0 was defined as a normal skin without any skin reaction; a 1+ reaction indicated minimum erythema and/or mild redness. Moderate redness with edema but no blistering or necrosis was represented by 2+. A 3+ reaction indicated redness, edema, and blistering. Patients with no skin reaction to skin photosensitivity tests, were allowed to be exposed to sunlight under careful surveillance at 1 week after PDT (10). Table 1 shows the summary of results of BAI-PDT.
RESULTS
Complete remission was obtained in all five patients with early-stage lung cancers, and partial remission was obtained in the two patients with advanced disease. Only one patient, (patient 4) showed mild, grade 1 photosensitivity.
There was no evidence ofskin photosensitivity in the other six patients.
Case Report
In this 81-year-old man (patient 1), lung cancer was initially diagnosed based on positive sputum cytologic findings during a mass screening program for individuals at risk for lung cancer. All roentgenographic examinations were negative. The tumor was nodular, 5 by 5 mm in size and located in the right B 6 (Fig. 1A) . It was treated by BAI-PDT using an excimer-dye laser at 100 J/cm2. The tumor disappeared completely and a CR was obtained (Fig. 1B) sensitizers in the skin. This skin reaction is potentially so severe that patients must be warned to avoid exposure to direct sunlight for several weeks (4) .
Preliminary studies in animals suggest that low doses (0.5 mg/kg) of Photofrin eliminate skin photosensitivity (13) ; in addition, Lam et al. (10) indicated that 0.25 mg/kg of Photofrin is enough to diagnose early-stage lung cancer without any skin photosensitivity (10) . On the other hand, the selective infusion yields a higher uptake of drug in tumor tissues. The platinum concentration in resected tumor specimens has been reported to be 2 to 4.5 times higher than in normal tissue, and clinical and histologic studies have shown a recognizable effect after BAI (8, 14, 15) . The Seldinger method is now used for puncture. Skill and experience should enable the endoscopist to successfully perform this even in patients with arteriosclerosis and anatomic abnormalities (8, 16) . Adverse reactions--intra-arterial infusion, infection and thrombosis around the insertion site of catheters, hemorrhage due to catheter damage, and intimal damage during insertion of cathetermmay occur; however, serious complications such as paralysis were not reported (16) . Therefore, to increase the concentration of drug in the tumor and decrease systemic distribution in the rest of the body, it seems logical to infuse the drug directly into the tumor-feeding bronchial artery.
Unfortunately, the photosensitizer pharmacokinetics and distribution in man are still unknown (17) ; however, an experimental study in dogs revealed that intra-arterial injection of Photofrin achieved higher Photofrin accumulation than intravenous injection (18 (10) suggested that there was a threshold for skin photosensitivity reaction between 0.25 and 2 mg/kg Photofrin; however, further work on dosemetry remains to be performed.
